Literature DB >> 27330506

Fulminant Colitis Following Rituximab Therapy.

Seth Lipka1, Seymour Katz2, James M Crawford3.   

Abstract

Entities:  

Year:  2016        PMID： 27330506      PMCID： PMC4865788     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  19 in total

1.  Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi; Hidetoshi Takedatsu; Richard S Blumberg; Atul K Bhan
Journal:  Immunity       Date:  2002-02       Impact factor: 31.745

2.  Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma.

Authors:  Piers Blombery; H Miles Prince; Michele Levinson; Stephen Pianko; Ellen Maxwell; Prithi Bhathal
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

3.  Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease.

Authors:  Daniel El Fassi; Claus H Nielsen; Jens Kjeldsen; Ole Clemmensen; Laszlo Hegedüs
Journal:  Gut       Date:  2008-05       Impact factor: 23.059

Review 4.  Regulatory B lymphocytes in humans: a potential role in autoimmunity.

Authors:  Christophe Jamin; Ahsen Morva; Sébastien Lemoine; Capucine Daridon; Agnès Revol de Mendoza; Pierre Youinou
Journal:  Arthritis Rheum       Date:  2008-07

5.  [Ulcerative colitis: exceptional consequence after rituximab therapy].

Authors:  Y Sekkach; S Hammi; M Elqatni; J Fatihi; M Badaoui; N Elomri; F Mekouar; J Smaali; M Jira; T Amezyane; A Abouzahir; D Ghafir
Journal:  Ann Pharm Fr       Date:  2011-07-23

Review 6.  Serologic markers in inflammatory bowel disease.

Authors:  Xavier Bossuyt
Journal:  Clin Chem       Date:  2005-12-08       Impact factor: 8.327

7.  Regulatory role of mature B cells in a murine model of inflammatory bowel disease.

Authors:  E Mizoguchi; A Mizoguchi; F I Preffer; A K Bhan
Journal:  Int Immunol       Date:  2000-05       Impact factor: 4.823

8.  Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.

Authors:  Keith Leiper; Kate Martin; Anthony Ellis; Sreedhar Subramanian; Alastair J Watson; Steve E Christmas; Deborah Howarth; Fiona Campbell; Jonathan M Rhodes
Journal:  Gut       Date:  2011-04-06       Impact factor: 23.059

9.  Exacerbation of ulcerative colitis after rituximab salvage therapy.

Authors:  Martin Goetz; Raja Atreya; Maryam Ghalibafian; Peter R Galle; Markus F Neurath
Journal:  Inflamm Bowel Dis       Date:  2007-11       Impact factor: 5.325

10.  T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.

Authors:  N J Davidson; M W Leach; M M Fort; L Thompson-Snipes; R Kühn; W Müller; D J Berg; D M Rennick
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307
View more
  4 in total

1.  Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells.

Authors:  Mathieu Uzzan; Huaibin M Ko; Adam K Rosenstein; Kamron Pourmand; Jean-Frederic Colombel; Saurabh Mehandru
Journal:  Ann N Y Acad Sci       Date:  2017-12-31       Impact factor: 5.691

2.  Commensalism or symbiosis: The potential use of rituximab in steroid-refractory Evans syndrome in a patient with ulcerative colitis.

Authors:  Eyad Ahmed; Kok Hoe Chan; Sindhusha Veeraballi; Theodore Dacosta; Hamid Shaaban
Journal:  Arch Rheumatol       Date:  2021-10-18       Impact factor: 1.007

Review 3.  Medication-associated gastrointestinal tract injury.

Authors:  Michael Vieth; Elizabeth Montgomery
Journal:  Virchows Arch       Date:  2017-01-30       Impact factor: 4.535

Review 4.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.